News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Business
Symphogen A/S Enters into Strategic Collaboration with Genentech, Inc. for Antibody Therapeutics in Infectious Disease
June 10, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
COPENHAGEN, Denmark--(BUSINESS WIRE)--Symphogen A/S announced today that it has entered into a global strategic collaboration with Genentech, Inc. for antibody therapeutics against three undisclosed infectious disease targets.
Twitter
LinkedIn
Facebook
Email
Print
Alliances
Europe
Genentech, Inc.
MORE ON THIS TOPIC
Earnings
Novo Vows Smoother Market Waters for Wegovy—but Analysts Are Skeptical
May 7, 2025
·
2 min read
·
Tristan Manalac
Manufacturing
Amid Trump’s Trade War, Some Drugmakers Stockpile Products in U.S.
May 7, 2025
·
2 min read
·
Tristan Manalac
Podcast
Trump’s US Manufacturing Push, New Vaccine Policy, Novo’s Weight Loss Pill up for FDA Review
May 7, 2025
·
1 min read
·
Heather McKenzie
Manufacturing
Trump Orders FDA To Ease US Plant Expansion; Drops Hammer on Foreign Inspections
May 6, 2025
·
3 min read
·
Annalee Armstrong